Tag:
Moncef Slaoui
Latest Headlines
Latest Headlines
Merck to invest in Canadian VC fund
It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.
GSK, J&J back Index's new $200M fund for early-stage deals
GlaxoSmithKline and Johnson & Johnson are teaming up with Index Ventures to launch a $200 million fund devoted exclusively to backing early-stage biotechs
GSK studies Chinese remedies to discover new drugs
Amid GlaxoSmithKline's ( $GSK ) major push to expand in China , the London-based drugmaker has located a new R&D unit in that country that will investigate traditional Chinese medicines. The move is
GSK's Slaoui opts for more flexible approach in DPU change-up
Now that GlaxoSmithKline ( $GSK ) has hit the three-year mark on its closely watched experiment with Drug Performance Units, R&D Chairman Moncef Slaoui (pictured) tells FierceBiotech the pharma
GSK will cut 3 R&D units, add 4 as DPU review triggers shakeup
Following a three-year review of its new approach to R&D, GlaxoSmithKline ( $GSK ) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a
GSK readies its much-anticipated 3-year review for DPUs
In one of the most anticipated R&D events of the year, GlaxoSmithKline ( $GSK ) execs are readying a summary judgment on the results of the first three-year round of results for their
GSK's new R&D culture forces research chiefs to hustle for support
Of all the Big Pharmas anxiously attempting to reinvent the way they discover and develop new drugs, few if any have been as ambitious about creating a new R&D culture as GlaxoSmithKline ( $GSK ).
GSK shakes up R&D units during high-profile review
After an overhaul of its research and development three years ago, GlaxoSmithKline ( $GSK ) has wrapped up a review this month of the 38 Discovery Performance Units (DPUs) that were created as nimble
Glaxo R&D chief Slaoui outlines his formula for success
Big Pharma's been debating for years over how to whip its massive and often woefully unproductive R&D bureaucracies into some kind of fighting shape similar to the lean, mean fighting machines
GSK laments M&A rush, pursues rare diseases
GlaxoSmithKline has already done a dozen deals since CEO Andrew Witty took over in 2008. But the Pharma giant would have pursued more deals if the price of acquiring novel drugs weren't so high.
